Keun Wook Lee

Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.

Josep Tabernero, Eric Van Cutsem, Yung‐Jue Bang et al. · Journal of Clinical Oncology · 2019 · 171 citations

Medicine, Oncology, Pharmacotherapy +14

Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.

Funda Meric‐Bernstam, Diana L. Hanna, Anthony B. El-Khoueiry et al. · Journal of Clinical Oncology · 2021 · 68 citations

Medicine, Oncology, Pharmacology +15

Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.

Yelena Y. Janjigian, Do‐Youn Oh, Sun Young Rha et al. · Journal of Clinical Oncology · 2022 · 42 citations · Full text

Medicine, Oncology, Pharmacology +17

Dedifferentiated liposarcoma of the liver

Yong Il Kim, Eun Sil Yu, Keun Wook Lee et al. · Cancer · 1987 · 39 citations · Full text

Veterinary Medicine, Oncology, Pathology +17

Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.

Funda Meric‐Bernstam, Erika Hamilton, Muralidhar Beeram et al. · Journal of Clinical Oncology · 2021 · 39 citations

Medicine, Oncology, Pharmacology +17